c-Met/HGFR
c-Met/HGFR-Inhibitoren zielen auf den Hepatozyten-Wachstumsfaktor-Rezeptor (c-Met) ab, eine Tyrosinkinase, die an zellulären Prozessen wie Wachstum, Beweglichkeit und Morphogenese beteiligt ist. Die c-Met-Signalgebung ist an der Krebsprogression, Metastasierung und Therapieresistenz beteiligt. Die Hemmung von c-Met kann das Tumorwachstum und die Ausbreitung stören, wodurch diese Inhibitoren in der Krebsforschung wertvoll sind. Bei CymitQuimica bieten wir c-Met/HGFR-Inhibitoren an, um Ihre Forschung in der Onkologie, Metastasierung und bei gezielten Krebstherapien zu unterstützen.
142 Produkte aus dem Bereich "c-Met/HGFR" gefunden
Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
CSF1R-IN-2
CAS:CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).Formel:C20H20FN7O2Reinheit:99.29%Farbe und Form:SolidMolekulargewicht:409.42Pamufetinib
CAS:Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Formel:C27H23FN4O4SReinheit:99.39%Farbe und Form:SolidMolekulargewicht:518.56Ref: TM-T13108
1mg52,00€5mg101,00€10mg149,00€25mg244,00€50mg359,00€100mg510,00€200mg695,00€1mL*10mM (DMSO)127,00€SU 5616
CAS:SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.
Formel:C13H8ClNOSReinheit:98.84%Farbe und Form:SoildMolekulargewicht:261.73Rilotumumab
CAS:Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.
Reinheit:SDS-PAGE:95% SEC-HPLC:97.51%Farbe und Form:LiquidMolekulargewicht:145.2 kDac-Met inhibitor 1
CAS:c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Formel:C17H14N8SReinheit:98.77%Farbe und Form:SolidMolekulargewicht:362.41Emibetuzumab
CAS:Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.Reinheit:SDS-PAGE:96.2%;SEC-HPLC:98.8%Farbe und Form:LiquidMolekulargewicht:143.74 kDaBozitinib
CAS:Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Formel:C20H15F3N8Reinheit:99.16%Farbe und Form:SolidMolekulargewicht:424.38Ref: TM-T10585
1mg92,00€5mg205,00€10mg334,00€25mg595,00€50mg858,00€100mg1.198,00€200mg1.611,00€1mL*10mM (DMSO)227,00€Onartuzumab
CAS:Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.Reinheit:97.3%Farbe und Form:LiquidMolekulargewicht:146.99 kDaJNJ-38877618
CAS:JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Formel:C20H12F2N6Reinheit:98.84% - 99.74%Farbe und Form:SolidMolekulargewicht:374.35Ref: TM-T15617
1mg59,00€5mg130,00€10mg200,00€25mg401,00€50mg557,00€100mg737,00€1mL*10mM (DMSO)144,00€Caveolin-1 (82-101) amide (human, mouse, rat)
CAS:Caveolin-1 (82-101) amide (human, mouse, rat), also known as Caveolin-1 scaffolding domain peptide, mitigates aging-related detrimental alterations in variousFormel:C124H170N28O29Reinheit:98%Farbe und Form:SolidMolekulargewicht:2516.85c-Met ligand-Linker Conjugate 1
c-Met ligand-Linker Conjugate 1 is a Target Protein Ligand-Linker Conjugate that consists of a c-Met ligand and a PROTAC linker, capable of recruiting E3 ligase. This compound is used in the synthesis of PROTACc-Met degrader-5.Farbe und Form:Odour SolidLMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Formel:C18H11F3N4OReinheit:99.58%Farbe und Form:SoildMolekulargewicht:356.3PROTAC c-Met degrader-1
CAS:PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.Formel:C45H41FN10O5Farbe und Form:SolidMolekulargewicht:820.87c-Met-IN-23
c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.Formel:C16H13N7OMolekulargewicht:319.11816PROTAC c-Met degrader-2
CAS:PROTACc-Met degrader-2 (PROTAC2) is a c-Met degrader developed using PROTAC technology, with a DC50 value of 50 nM.Formel:C51H50F2N6O13Farbe und Form:SolidMolekulargewicht:992.97Norleual
CAS:Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.
Formel:C41H58N8O7Reinheit:98%Farbe und Form:SolidMolekulargewicht:774.95Fosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Formel:C29H49N4O10PReinheit:98.01%Farbe und Form:SolidMolekulargewicht:644.69Ref: TM-T39507L
1mg116,00€2mg160,00€5mg238,00€10mg353,00€25mg563,00€50mg758,00€100mg1.017,00€200mg1.359,00€BMS-777607
CAS:BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.Formel:C25H19ClF2N4O4Reinheit:98.16% - 98.56%Farbe und Form:SolidMolekulargewicht:512.89Ref: TM-T2658
2mg59,00€5mg86,00€10mg135,00€25mg251,00€50mg388,00€100mg690,00€200mg1.034,00€500mg1.550,00€PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Formel:C51H54N10O7Farbe und Form:SolidMolekulargewicht:919.037PF-04217903 phenolsulfonate
CAS:PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Formel:C25H22N8O5SReinheit:98%Farbe und Form:SolidMolekulargewicht:546.56
